➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Merck
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for AZD9977


Email this page to a colleague

« Back to Dashboard

What is the drug development status for AZD9977?

AZD9977 is an investigational drug.

There have been 13 clinical trials for AZD9977. The most recent clinical trial was a Phase 1 trial, which was initiated on November 12th 2020.

The most common disease conditions in clinical trials are Heart Failure, Cardiovascular Diseases, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.

There are two US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for AZD9977
TitleSponsorPhase
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy VolunteersParexelPhase 1
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy VolunteersAstraZenecaPhase 1
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male SubjectsQuotient SciencesPhase 1

See all AZD9977 clinical trials

Clinical Trial Summary for AZD9977

Top disease conditions for AZD9977
Top clinical trial sponsors for AZD9977

See all AZD9977 clinical trials

US Patents for AZD9977

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD9977 ⤷  Free Forever Trial Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE) ⤷  Free Forever Trial
AZD9977 ⤷  Free Forever Trial Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD9977

Drugname Country Document Number Estimated Expiration Related US Patent
AZD9977 Argentina AR101036 2034-06-30 ⤷  Free Forever Trial
AZD9977 Australia AU2015282450 2034-06-30 ⤷  Free Forever Trial
AZD9977 Canada CA2953655 2034-06-30 ⤷  Free Forever Trial
AZD9977 China CN106536491 2034-06-30 ⤷  Free Forever Trial
AZD9977 Cyprus CY1121596 2034-06-30 ⤷  Free Forever Trial
AZD9977 Denmark DK3160948 2034-06-30 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.